HomeArticles posted by Mike Burke(Page 16)

Officer/Director Liability for Violations of the US Federal Food, Drug, and Cosmetic Act

June 3, 2015June 3, 2016 Mike Burke Life Sciences doing business in the united states, doing business in the united states, ireland doing business in the united states, ireland export, ireland exporter, ireland us affiliate, irish export, irish exporter, northern ireland doing business , FDA, ireland doing business in the united states, ireland export, ireland exporter, ireland us affiliate, northern ireland doing business in the united states, northern ireland export, northern ireland exporter, northern ireland us affiliate, US affiliate

Officers and directors of Irish and Northern Irish companies whose products would be regulated by the US Food and Drug Administration (life sciences companies, specifically) should be aware of developments on the issue of individual prosecution under the FDCA for company violations of that statute. AGG partner Alan Minsk and associate Alex Foster have written an update that is new to AGG’s Knowledge Center. Continue reading →

Certain Health Insurance Reimbursements Prohibited- Immediate Action Required for Irish/NI Companies with US Employees

May 20, 2015June 3, 2016 Mike Burke Employment, Formation Issues employment, Forming an Affiliate

Irish and Northern Irish companies with employees in the US need to read this update and take immediate action if needed. And I’m not just writing that because I’m the proprietor of this blog! Continue reading →

Protecting Your Trade Secrets in the US

May 14, 2015May 25, 2016 Mike Burke Intellectual Property, Nondisclosure Agreements, Smart Exporting doing business in the united states, intellectual property, ireland doing business in the united states, ireland export, ireland exporter, ireland us affiliate, NDAs, northern ireland doing business in the united states, northern ireland export, northern ireland exporter, northern ireland us affiliate, risk mitigation, Smart Exporting, trade secrets, US affiliate

Remember earlier posts about non-disclosure agreements, and the role they play in defining and protecting trade secrets? Of course you do—but in case you don’t, one of them is here. I even drafted a brief two-page outline for NDAs, here.

The macro point of those posts, at least as to protecting trade secrets, is that in the US, a trade secrets owner must take all “reasonably available steps” to protect their trade secrets. In an unpublished opinion filed on May 8, 2015, the US Court of Continue reading →